



Contact: CEOcast, Inc.  
Gary Nash  
Investor Relations  
212-732-4300  
gnash@ceocast.com

## **ImmunoCellular Therapeutics, Ltd. To Present at the OneMedForum and the Biotech Showcase Next Week**

**LOS ANGELES, CA – January 8, 2010** – ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC) a biotechnology company that is focused on the development of novel immune-based cancer therapies, announced today that it will present at the OneMedForum 2010 Emerging Company Finance Conference on Wednesday, January 13 at the Sir Francis Drake Hotel in San Francisco, CA in the Windsor & Renaissance Rooms.

Manish Singh, Ph.D., President and CEO of the Company, will present a corporate overview at 4:15 p.m. in addition to providing a clinical update highlighting some of the recent positive clinical results that the Company's innovative portfolio of cancer immunotherapies have displayed, including results from Phase I testing in ICT-107, which was demonstrated to significantly increase life expectancy in patients with glioblastoma compared to the current standard of care.

Information about the conference along with the Company's webcast may be found at <http://www.onemedplace.com>.

The Company will also present on Tuesday, January 12th at 2 p.m. at the Biotech Showcase 2010. The event will take place at the Marines' Memorial Club and Hotel in San Francisco. Additional information can be found at <http://www.ebdgroup.com/bts/prscomps.htm>.

### About ImmunoCellular Therapeutics

IMUC is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. The Company recently completed a Phase I trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor associated antigens for glioblastoma. The Company is planning to initiate a multicenter phase II study in the second half of 2010. The Company's "off the shelf" therapeutic vaccine product candidate (ICT-121) targeting cancer stem cells for multiple cancer indications is targeted by IMUC to enter clinical trials for glioblastoma during the second half of 2010. IMUC has entered into a research and license option deal with the Roche Group for one of the Company's monoclonal antibody product candidates for the diagnosis and treatment of ovarian cancer and multiple myeloma, which provides for potential licensing and milestone payments of \$32MM and royalties if the Roche Group exercises its option and commercializes this antibody technology for multiple indications. IMUC is in pre-clinical development of another monoclonal antibody product candidate for the treatment of small cell lung cancer and pancreatic cancer, and is also evaluating its platform technology for

monoclonal antibody discovery to target cancer stem cells. To learn more about IMUC, please visit [www.imuc.com](http://www.imuc.com).

### Forward-Looking Statements

This press release contains certain forward-looking statements that are subject to a number of risks and uncertainties, including without limitation, the risks associated with the potential inability to obtain licenses from third parties that will be needed to commercialize ICT-107 in many major commercial territories; the potential inability to secure a partner to fund development and marketing of ICT-107; the risk that future trials of ICT-107, if any, do not confirm the safety and efficacy data generated in the Phase I trial; the need to satisfy performance milestones to maintain the vaccine technology licenses with Cedars-Sinai; the risks associated with obtaining a patent that provides commercially significant protection for ICT-107; the risk of encountering substantial delays in completing or being unable to successfully complete the pre-clinical testing necessary before initiating clinical testing of ICT-121; and the need for substantial additional capital to fund development of product candidates beyond their initial clinical or pre-clinical stages and to continue IMUC's operations. Additional risks and uncertainties are described in IMUC's most recently filed SEC documents, such as its most recent annual report on Form 10-K, all quarterly reports on Form 10-Q and any current reports on Form 8-K. IMUC undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

###